Skip to main content
. Author manuscript; available in PMC: 2021 Sep 19.
Published in final edited form as: Prog Retin Eye Res. 2021 Feb 25;84:100954. doi: 10.1016/j.preteyeres.2021.100954

Table 1.

Currently approved and emerging anti-VEGF therapies and ongoing clinical trials.

Drug Molecular Features Approval Status Ongoing Trials
Ranibizumab (LUCENTIS) Fab against all VEGF-A isotypes First approval 2006 LUMINOUS – observational study
Multiple retinal disease indications Control arms for multiple emerging anti-VEGFs and other targets
Aflibercept (EYLEA) Fusion protein against all VEGF-A isotypes, VEGF-B and PlGF First approval 2011 Multiple observational studies
Multiple retinal disease indications Control arms for multiple emerging anti-VEGFs and other targets
Brolucizumab (BEOVU) scFv against all VEGF-A isotypes First approval 2019 nAMD Multiple trials initiated/planned in DME, RVO, and T&E trials in nAMD
Conbercept Fusion protein against all VEGF-A isotypes and PlGF Approval (China) 2013 nAMD Phase III
Abicipar DARPin against all VEGF-A isotypes Phase III Phase III development in nAMD (not approved by FDA [June 2020])
Faricimab Antibody against VEGF-A and anti-Ang2 Phase III Phase III development in nAMD and DME

Ang2, angiopoietin-2; DARPin, designed ankyrin repeat protein; DME, diabetic macular edema; Fab, monoclonal antibody fragment; nAMD, neovascular age-related macular degeneration; PlGF, placental growth factor; RVO, retinal vein occlusion; scFv, single-chain variable fragment; T&E, treat and extend; VEGF-A, vascular endothelial growth factor-A.